1stOncology™: Cancer Intelligence Service – Page 13253 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Thermo Fisher Scientific Prices Offering of Senior Notes

On September 25, 2019 Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") reported that it has priced an offering of €4.4 billion aggregate principal amount (the "Euro Offering") of euro-denominated notes (collectively, the "Euro Notes") and an offering of $900 million aggregate principal amount (the "USD Offering" and, together with the Euro Offering, the "Offerings") of USD-denominated notes (collectively, the "USD Notes") (Press release, Thermo Fisher Scientific, SEP 25, 2019, View Source [SID1234539771]). The following notes were priced:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

€800 million aggregate principal amount of its 0.125% senior notes due 2025, at the issue price of 99.114% of their principal amount,
€800 million aggregate principal amount of its 0.500% senior notes due 2028, at the issue price of 99.060% of their principal amount,
€900 million aggregate principal amount of its 0.875% senior notes due 2031, at the issue price of 99.243% of their principal amount,
€900 million aggregate principal amount of its 1.500% senior notes due 2039, at the issue price of 99.743% of their principal amount,
€1,000 million aggregate principal amount of its 1.875% senior notes due 2049, at the issue price of 98.465% of their principal amount, and
$900 million aggregate principal amount of its 2.600% senior notes due 2029, at the issue price of 99.861% of their principal amount.
The Euro Offering is expected to close on or about September 30, 2019, and the USD Offering is expected to close on or about October 8, 2019, subject to customary closing conditions. The Euro Notes will pay interest on an annual basis. The USD Notes will pay interest on a semi-annual basis. Closing of the Euro Offering is not contingent upon the completion of the USD Offering, and closing of the USD Offering is not contingent upon the completion of the Euro Offering.

Thermo Fisher intends to use the net proceeds of the Offerings (together with cash on hand) to repay commercial paper issued to fund the redemption on September 27, 2019, of $300 million aggregate principal amount of its 4.70% Senior Notes due 2020 and $800 million aggregate principal amount of its 3.15% Senior Notes due 2023, and to fund the redemption of approximately $4.5 billion aggregate principal amount of outstanding senior notes issued by Thermo Fisher or its subsidiaries, including all of the outstanding 6.00% Senior Notes due 2020 and 5.00% Senior Notes due 2021 issued by its subsidiary Life Technologies Corporation, of which notice is expected to be provided to holders tomorrow.

The joint book-running managers for the Euro Offering are Goldman Sachs & Co. LLC, Merrill Lynch International, Citigroup Global Markets Limited and J.P. Morgan Securities plc. The joint book-running managers for the USD Offering are Goldman Sachs & Co. LLC, BofA Securities, Inc., Credit Suisse Securities (USA) LLC and HSBC Securities (USA) Inc.

The Offerings are being made pursuant to an effective registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission (the "SEC"). Prospective investors should read the prospectus forming a part of that registration statement and the separate prospectus supplements related to the Offerings and the other documents that Thermo Fisher has filed with the SEC for more complete information about Thermo Fisher and the Offerings. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Thermo Fisher, the underwriters or any dealer participating in the Euro Offering will arrange to send you the related prospectus if you request it by calling Merrill Lynch International toll-free at 1-800-294-1322; Goldman Sachs & Co. LLC toll-free at 1-866-471-2526; Citigroup Global Markets Limited toll-free at 1-800-831-9146; or J.P. Morgan Securities plc collect on +44-207-134-2468; and Thermo Fisher, the underwriters or any dealer participating in the USD Offering will arrange to send you the related prospectus if you request it by calling BofA Securities, Inc. toll-free at 1-800-294-1322; Goldman Sachs & Co. LLC toll-free at 1-866-471-2526; Credit Suisse Securities (USA) LLC at 1-800-221-1037; or HSBC Securities (USA) Inc. toll-free at 1-866-811-8049.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Selecta Biosciences to Participate in Two Investor Conferences in October

On September 25, 2019 Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, reported that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the following upcoming investor conferences in October (Press release, Selecta Biosciences, SEP 25, 2019, View Source [SID1234539770]).

Event: 2019 Cantor Global Healthcare Conference
Date: Wednesday, October 2, 2019
Presentation Time: 10:40 a.m. Eastern Time
Location: New York City

Event: Chardan’s 3rd Annual Genetic Medicines Conference
Date: Tuesday, October 8, 2019
Presentation Time: 10:30 a.m. Eastern Time
Location: New York City

To access copies and the live webcasts of Selecta’s presentations, please visit the Investors & Media section of the Selecta website at www.selectabio.com. Replays of the webcasts will be available on the Selecta website for 90 days following the events.

TRILLIUM THERAPEUTICS APPOINTS JAN SKVARKA AS PRESIDENT AND CHIEF EXECUTIVE OFFICER REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

On September 25, 2019 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported the appointment of Mr. Jan Skvarka as President and Chief Executive Officer effective today (Press release, Trillium Therapeutics, SEP 25, 2019, View Source [SID1234539769]). Mr. Skvarka has also been appointed to the Board of Directors of the company.

"We are delighted to welcome Mr. Skvarka to Trillium," said Robert L. Kirkman, M.D., Executive Chair of Trillium. "We are looking forward to his leadership as we continue to advance the clinical development of TTI-621, our novel CD47 immune checkpoint inhibitor. We believe his long experience in healthcare and finance will be invaluable as we position Trillium for the future."

Added Mr. Skvarka, "I am thrilled at the opportunity to join Trillium, which has positioned itself as a leading CD47-focused immuno-oncology company. TTI-621 is a unique and differentiated molecule that has shown promising results as a monotherapy in early-stage studies in both T- and B-cell lymphomas. I look forward to working with the Trillium team and Board of Directors to take this promising investigational therapy to the next stage of clinical development, and, ultimately, to patients."

Before joining Trillium, Mr. Skvarka was President and Chief Executive Officer of Tal Medical, a clinical-stage neuroscience company in Boston, Massachusetts, from 2014 until 2018. Prior to that he had a long career from 1999 to 2013 as a healthcare consultant at Bain & Company, Boston. He was a partner in the Bain Healthcare practice from 2007 until 2013, with a focus on pharmaceutical, biotechnology and medical technology companies. Earlier in his career he worked in the corporate finance arm of Price Waterhouse in London, UK and Vienna, Austria. Mr. Skvarka holds an MBA degree from Harvard Business School.

Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Effective September 25, 2019, the Board of Directors adopted the Trillium Therapeutics Inc. 2019 Inducement Stock Option Plan, or the 2019 Inducement Plan, under which Trillium may grant inducement equity awards outside of Trillium’s current stockholder-approved stock option and incentive plans.

The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Trillium (or following a bona fide period of non-employment) as an inducement material to such individual’s entering into employment with Trillium in accordance with Nasdaq Listing Rule 5635(c)(4).

In connection with the appointment of Mr. Skvarka as Chief Executive Officer, the Board of Directors has granted to Mr. Skvarka an option to purchase 1,800,000 common shares under the 2019 Inducement Plan at an exercise price equal to the closing market price of Trillium’s common shares on September 24, 2019. One quarter of the stock options vest 12 months after the date of grant and 1/48th of the remaining options vest each month for the following three years, subject to his continued service with Trillium on such vesting dates. Other terms of the stock option grant are as determined by the Board of Directors and set forth in the 2019 Inducement Plan and applicable award agreement covering such grant. The award is intended to qualify as an "employment inducement award" within the meaning of Nasdaq Listing Rule 5635(c)(4).

Spectrum Pharmaceuticals to Present Corporate Update at the 2019 Cantor Global Healthcare Conference on October 2nd

On September 25, 2019 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported that an overview of the company’s business strategy and development-stage programs will be given at the 2019 Cantor Global Healthcare Conference being held in New York (Press release, Spectrum Pharmaceuticals, SEP 25, 2019, http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-present-corporate-update-2019-cantor [SID1234539768]). The company presentation is on Wednesday, October 2, 2019 at 2:25 PM EDT.

The presentations will be webcast live and may be accessed by visiting Spectrum’s website at View Source

Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

On September 25, 2019 Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) reported that it will showcase data from its proprietary clinical programs at the 2019 European Society for Medical Oncology Congress ("ESMO") on September 27 to October 1, 2019 in Barcelona, Spain (Press release, Hutchison China MediTech, SEP 25, 2019, View Source [SID1234539767]).

A key highlight will be the oral presentation of a Late-Breaking Abstract reporting efficacy and safety results from the positive Phase III trial in China of surufatinib in non-pancreatic neuroendocrine tumors ("NET"), known as SANET-ep. An interim analysis in June 2019 confirmed that the study met its primary endpoint of progression-free survival ("PFS"). As a result, the independent data monitoring committee ("IDMC") recommended the study be stopped, a year ahead of schedule, and preparations are now underway for the submission of a New Drug Application ("NDA") by the end of 2019 for this indication in China.

The Late-Breaking Abstract will be published on the ESMO (Free ESMO Whitepaper) website coincident with the its presentation; the details of which are as follows:

Title:

Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic Neuroendocrine Tumors: Results from the Randomized Phase III Study (SANET-ep)

Presenting Author:

Jianming Xu, Head of the Department of Gastrointestinal Oncology, The Fifth Medical Center, General Hospital of the PLA

Abstract #:

LBA76

Date & Time:

Sunday, September 29, 2019, 16:30 CEST

Location:

Tarragona Auditorium (Hall 7), Fira de Barcelona Gran Via Conference Centre

A conference call and webcast for analysts and investors will be held on Monday September 30, 1 p.m. U.K. time (2 p.m. Barcelona time; 8 a.m. New York time; 8 p.m. Hong Kong time) to review the SANET-ep trial data presented on Sunday, September 29. Safety and tolerability data presented from an ongoing U.S. Phase Ib study of surufatinib in pancreatic NET patients who have progressed on Sutent or Afinitor treatment will also be discussed.

Participating in the call will be Dr. James Yao, Chair of GI Oncology at MD Anderson Cancer Center and one of the lead investigators for our ongoing Phase I/Ib surufatinib study in NET, as well as members of the Chi-Med management team. Dial-in details for the conference call will be available prior to the event at www.chi-med.com/event-information, and a replay will also be available shortly after.

Details of the abstract for the U.S. Phase Ib trial of surufatinib in pancreatic NET patients are as follows:

Title:

Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors

Presenting Author:

Erika P. Hamilton, Director, Breast and Gynecologic Cancer Research at Sarah Cannon Research Institute

Abstract # & Link:

1393P

Date & Time:

Sunday, September 29, 2019, 12:00 CEST

Location:

Hall 4, Fira de Barcelona Gran Via Conference Centre

Other Clinical Data Abstracts

Fruquintinib in the U.S. and Europe: Safety and tolerability of fruquintinib in Western patients with solid tumors will be presented. Fruquintinib is currently in planning for a Phase III registration study in the U.S. and Europe in metastatic colorectal cancer ("CRC") patients who are resistant to or intolerant of prior treatment with Stivarga or Lonsurf. In China, fruquintinib is currently sold under the brand name Elunate, and is for the treatment of patients with metastatic CRC that have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan, including those who have previously received anti-VEGF therapy and/or anti-EGFR therapy (RAS wild type).

Title:

Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase

Presenting Author:

Andrea Wang-Gillam, Associate Professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine

Abstract #:

467P

Date & Time:

Saturday, September 28, 2019, 12:00 CEST

Location:

Hall 4, Fira de Barcelona Gran Via Conference Centre

Chi-Med retains all rights to surufatinib worldwide. It retains all rights to fruquintinib outside of China and is partnered with Eli Lilly and Company in China.

Trials-in-Progress Abstracts

Title:

A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma

Lead Author:

Nathan Fowler, Associate Professor, Department of Lymphoma/Myeloma, the University of Texas MD Anderson Cancer Center

Abstract #:

1106TiP

Date & Time:

Saturday, September 28, 2019, 12:00 CEST

Location:

Hall 4, Fira de Barcelona Gran Via Conference Centre

Title:

A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma

Lead Author:

Jonathan B. Cohen, Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Abstract #:

1107TiP

Date & Time:

Saturday, September 28, 2019, 12:00 CEST

Location:

Hall 4, Fira de Barcelona Gran Via Conference Centre

About SANET-ep

SANET-ep is a randomized, double-blind, placebo-controlled, multi-center, Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic patients in China for whom there is no effective therapy. In June 2019, an interim analysis was conducted, leading to the IDMC determination that the study met the pre-defined primary endpoint of PFS and should be stopped early. Preparations for an NDA submission are now underway for this indication in China. In this study, patients with low- or intermediate-grade advanced extra-pancreatic neuroendocrine tumors for whom there is no effective therapy are randomized at a 2:1 ratio to receive either 300 mg of surufatinib orally daily or placebo, on a 28-day treatment cycle. The primary endpoint of the study is to evaluate the PFS, with secondary endpoints including objective response rate (ORR), disease control rate (DCR), time to response (TTR), duration of response (DoR), overall survival (OS), safety, and tolerability. Additional details may be found at clinicaltrials.gov, using identifier NCT02588170.